Trial Profile
Pilot, Single-arm, Non-comparative, Open-label Study of Daclizumab in Combination With Mycophenolate Mofetil and Sirolimus in the Prevention of Acute Rejection in Cardiac Allografts Recipients in Risk of Deteriorated Renal Function
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2015
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Mycophenolate mofetil (Primary) ; Sirolimus (Primary)
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Sponsors Roche
- 23 Jun 2006 New trial record.